A promising outlook for diabetic kidney disease

The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure

(2018) Merlin C. Thomas et al.   DIABETOLOGIA

Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial

(2018) Katherine R Tuttle et al.   Lancet Diabetes & Endocrinology

Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials

(2018) Vlado Perkovic et al.   Lancet Diabetes & Endocrinology

ASK1 contributes to fibrosis and dysfunction in models of kidney disease

(2018) John T. Liles et al.   JOURNAL OF CLINICAL INVESTIGATION

The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial

(2017) Rohit Loomba et al.   HEPATOLOGY

Shifts in podocyte histone H3K27me3 regulate mouse and human glomerular disease

(2017) Syamantak Majumder et al.   JOURNAL OF CLINICAL INVESTIGATION

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

(2017) Bruce Neal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial

(2017) David Z I Cherney et al.   Lancet Diabetes & Endocrinology